Stammdaten
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Unternehmen & Branche
| Name | NORTHWEST BIOTHERAPEUTICS INC |
|---|---|
| Ticker | NWBO |
| CIK | 0001072379 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 66737p600 |
|---|---|
| ISIN | US66737P6007 |
| Typ | Common Stock |
| Marktkapitalisierung | 321,2 Mio. USD |
| Beta | -0,77 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,378,000 | -60,162,000 | -0.04 | 81,290,000 | -60,280,000 |
| 2025-09-30 | 10-Q | 200,000 | -26,829,000 | -0.02 | 30,609,000 | -108,648,000 |
| 2025-06-30 | 10-Q | 131,000 | -15,378,000 | -0.01 | 29,547,000 | -100,389,000 |
| 2025-03-31 | 10-Q | 375,000 | -19,343,000 | -0.01 | 27,505,000 | -99,479,000 |
| 2024-12-31 | 10-K | 1,382,000 | -83,778,000 | -0.07 | 26,728,000 | -94,487,000 |
| 2024-09-30 | 10-Q | 357,000 | -19,374,000 | -0.02 | 29,321,000 | -80,117,000 |
| 2024-06-30 | 10-Q | 510,000 | -17,869,000 | -0.02 | 28,225,000 | -76,497,000 |
| 2024-03-31 | 10-Q | 284,000 | -18,312,000 | -0.02 | 28,567,000 | -73,282,000 |
| 2023-12-31 | 10-K | 1,932,000 | -62,599,000 | -0.06 | 27,865,000 | -65,773,000 |
| 2023-09-30 | 10-Q | 406,000 | -23,522,000 | -0.02 | 31,492,000 | -70,061,000 |
| 2023-06-30 | 10-Q | 201,000 | -14,448,000 | -0.01 | 28,438,000 | -61,034,000 |
| 2023-03-31 | 10-Q | 880,000 | -10,652,000 | -0.01 | 32,871,000 | -55,978,000 |
| 2022-12-31 | 10-K | 1,683,000 | -105,032,000 | -0.10 | 31,323,000 | -128,103,000 |
| 2022-09-30 | 10-Q | 206,000 | -32,852,000 | -0.03 | 31,098,000 | -108,850,000 |
| 2022-06-30 | 10-Q | 477,000 | -29,668,000 | -0.01 | 27,521,000 | -91,666,000 |
| 2022-03-31 | 10-Q | 403,000 | -14,214,000 | -0.01 | 30,658,000 | -120,525,000 |
| 2021-12-31 | 10-K | 1,005,000 | 179,126,000 | -0.06 | 40,160,000 | -123,991,000 |
| 2021-09-30 | 10-Q | 350,000 | 45,519,000 | -0.01 | 28,221,000 | -301,733,000 |
| 2021-06-30 | 10-Q | 416,000 | 4,410,000 | -0.01 | 28,767,000 | -349,842,000 |
| 2021-03-31 | 10-Q | 239,000 | -4,123,000 | 0.00 | 32,460,000 | -353,200,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 30.09.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| Moloney Securities Asset Management, LLC | 534,710 | 128,437 | 98.16 |
| KLCM Advisors, Inc. | 10,000 | 2,402 | 1.84 |